Treatment of opioid use disorder is challenging as many prescribing barriers exist that limit a patient’s access to treatment. This application-based continuing pharmacy education course will provide a ‘journal club format’ discussion for pharmacists, student pharmacists, and residents to compare extended-release naltrexone to the more restricted agent buprenorphine-naloxone in the X:BOT trial. Join us to discuss the importance of increasing access to this much needed treatment as well as the role of pharmacists in educating prescribers about all treatment options for opioid-use disorder.
- The BUZZ / News
- Publications
- MarketplaceAutomationCompoundingContamination ControlDelivery & ShippingDistributionFacilitiesFinanceManufacturingMerchandisingPatient CareHighlighted Practice SettingsProfessional DevelopmentProfessional ServicesSoftware
- Business Management, Operations, ERP
- Clinical Monitoring, Surveillance, Insights
- Controlled Substance Reporting
- Clinical Decision Support, Point of Care Reference, Dosing, DUR
- Drug Diversion Monitoring, Diversion Prevention
- Error Prevention, Drug Validation
- eMAR, EMR, EHR, Bedside Verification
- Formulary Management
- IV Workflow Management
- Long-Term Care Operation Management
- Medication Inventory Management & Procurement
- Pharmacy Management Systems, Workflow
- Stewardship Resources (Antibiotic, Opioid, etc)
Unit DoseWorkflow - Multimedia Content
- Career Center
- Market Intelligence
- Company
